Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up

• Autors principals: Amber Litzroth (Autor), Vanessa Suin (Autor), Chloé Wyndham-Thomas (Autor), Sophie Quoilin (Autor), Gaëtan Muyldermans (Autor), Thomas Vanwolleghem (Autor), Benoît Kabamba-Mukadi (Autor), Vera Verburgh (Autor), Marjorie Jacques (Autor), Steven Van Gucht (Autor), Veronik Hutse (Autor)
• Format: Llibre
• Publicat: BMC, 2019-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Background Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 199...